PMI韓國呼籲對加熱菸製定單獨規範

PMI PMK 加熱菸 iQOS

近日,Philip Morris韓國公司在宣傳其 iQOS 已獲得美國食品藥品監督管理局(FDA)授權的同時,呼籲政府應針對加熱菸草製品製定單獨的規範。

今年7月FDA授權菲莫國際的加熱菸草製品作為一種改良風險煙草產品(MRTP)進行行銷,這是菸草產業第二款通過MRTP的菸草產品。該公司表示,將提供FDA所需的任何其他信息,以獲得iQOS作為「降低風險」產品的市場推廣權。

PMK常務董事Paik Young-jay在現場直播的新聞發布會上表示「如果成年吸菸者獲得了錯誤的資訊,並且沒有使用無煙代用品/減害菸品的菸害防制政策來幫助他們,他們將繼續抽普通香菸,這是最有害的選擇。」

該公司再次呼籲政府追隨美國的腳步,根據科學證據制定政策。

近幾個月來,韓國已經提出了多項法案,以加強對加熱菸草製品的規範,包括增加稅收和要求貼有健康警示標籤。

FDA已經承認,這些產品已經「改變了」與菸草使用有關的風險,而PMK正在推動當局認識到,這種風險不僅改變了,而且「減少了。」

PMK還指出,FDA一般不會批准菸草產品,而iQOS也不是沒有風險的。

Philip Morris Korea says iQOS brings ‘reduced risk’

Calls for separate regulations for heated cigarettes citing FDA’s recognition of ‘modified risk’

Managing Director at Philip Morris Korea Paik Young-jay (Philip Morris Korea)

Philip Morris Korea on Wednesday called on the government to introduce separate regulations for heat-not-burn cigarettes as it touted the authorization by the US Food and Drug Administration of its Iqos.

The FDA decided in July to authorize the marketing of the company’s electronically heated tobacco system as a modified risk tobacco product as the industry’s first. The company said it will also provide any additional information required by the FDA to acquire the right to market Iqos as “reduced risk” products going forward.

“If adult smokers are given incorrect information and policy to help them switch (to electronic cigarettes) doesn’t exist, they will continue to smoke regular cigarettes, which is the most harmful [choice],” said Paik Young-jay, Managing Director at PMK during a livestreamed press conference.

The company refreshed calls on the government to follow the footsteps of the US and set policies based on scientific evidence.

The comments come as the government has proposed multiple bills in recent months to toughen regulations on heated cigarettes, including a tax increase and requiring health warning labels.

The FDA has acknowledged the products have “modified” the risk associated with tobacco use, while PMK is pushing for the authority to recognize the risk has not only been modified but also “reduced.”

PMK also noted that the FDA itself doesn’t “approve” of tobacco products in general and that Iqos is also not risk-free.

延伸閱讀:

‘FDA designation of IQOS as modified risk should change regulatory regime’

PMI執行長:紙菸10-15年內淘汰

PMI建議增加iQOS較健康描述 遭WHO拒絕

韓國香菸漲價 銷量下滑14.7%

韓國菸草KT&G:2025年成為世界第四大菸草公司

支持網站營運廣告

 FB留言板
支持網站營運廣告
支持網站營運廣告
支持網站營運廣告

發佈留言

發佈留言必須填寫的電子郵件地址不會公開。 必填欄位標示為 *